Purpose: To compare the anatomical and functional outcomes of posterior sub-Tenon triamcinolone (PST) in the treatment of pseudophakic cystoid macular edema (PCME) between diabetic and non-diabetic patients.
Methods: This retrospective study reviewed the medical records of patients who received PST for PCME following uncomplicated phacoemulsification with intraocular lens implantation between 2018 and 2021, with a minimum follow-up period of six months. A total of 43 eyes were included: 24 from non-diabetic patients (Group 1) and 19 from diabetic patients without diabetic retinopathy (Group 2). The mean HbA1c level in the diabetic group was 7.4 ± 1.1%, indicating moderately controlled diabetes. Best-corrected visual acuity (BCVA, LogMAR), central macular thickness (CMT), and intraocular pressure (IOP) were assessed at baseline and at 1, 3, and 6 months after PST treatment.
Results: Both groups demonstrated statistically significant improvements in BCVA and reductions in CMT at all follow-up visits (p < 0.05). In Group 1, mean CMT decreased from 412 ± 144 μm to 296 ± 65 μm, and BCVA improved from 0.64 ± 0.22 to 0.14 ± 0.08. Similarly, in Group 2, mean CMT decreased from 426 ± 154 μm to 301 ± 70 μm, and BCVA improved from 0.69 ± 0.26 to 0.15 ± 0.07. No significant intergroup differences were observed in changes in BCVA or CMT (p > 0.05). Intraocular pressure remained stable throughout the follow-up period in both groups.
Conclusions: The findings indicate that the presence of diabetes mellitus without retinopathy does not significantly influence the anatomical or functional response to PST therapy in patients with PCME. PST appears to be an effective and well-tolerated second-line treatment for PCME in both diabetic and non-diabetic patients following uncomplicated cataract surgery.
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号